Country: United States
Language: English
Source: NLM (National Library of Medicine)
ARTEMETHER (UNII: C7D6T3H22J) (ARTEMETHER - UNII:C7D6T3H22J)
Department of State Health Services, Pharmacy Branch
ARTEMETHER
ARTEMETHER 20 mg
PRESCRIPTION DRUG
New Drug Application
COARTEM- ARTEMETHER AND LUMEFANTRINE TABLET DEPARTMENT OF STATE HEALTH SERVICES, PHARMACY BRANCH ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE COARTEM TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR COARTEM TABLETS. COARTEM (ARTEMETHER/LUMEFANTRINE) TABLETS INITIAL U.S. APPROVAL: 2009 INDICATIONS AND USAGE Coartem (artemether and lumefantrine) Tablets are indicated for treatment of acute, uncomplicated malaria infections due to _Plasmodium falciparum_ in patients of 5 kg bodyweight and above. ( 1) Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported. ( 1) Coartem Tablets should not be used to treat severe malaria or to prevent malaria. ( 1) DOSAGE AND ADMINISTRATION Coartem Tablets should be taken with food. ( 2.1, 5.2) Tablets may be crushed and mixed with 1 to 2 teaspoons of water immediately prior to administration to patients, including children. ( 2.1) Coartem Tablets should be administered over 3 days for a total of 6 doses: an initial dose, second dose after 8 hours and then twice-daily (morning and evening) for the following 2 days. ( 2.2, 2.3) The adult dosage for patients with bodyweight of 35 kg and above is 4 tablets per dose for a total of 6 doses. ( 2.2) The number of tablets per dose for children is determined by bodyweight, as shown in the chart below. ( 2.3) TABLETS PER DOSE BY BODYWEIGHT; TOTAL OF 6 DOSES OVER 3 DAYS 5 to <15 kg 1 tablet 15 to <25 kg 2 tablets 25 to <35 kg 3 tablets 35 kg and over 4 tablets DOSAGE FORMS AND STRENGTHS Tablets are scored and contain 20 mg artemether and 120 mg lumefantrine. ( 3) CONTRAINDICATIONS Known hypersensitivity to artemether, lumefantrine, or to any of the excipients. ( 4) Coadministration of strong inducers of CYP3A4 such as rifampin, carbamazepine, phenytoin, and St. John’s wort with Coartem Tablets. ( 4, 7.1, 12.3) WARNINGS AND PRECAUTIONS Avoid use in patients with known QT prolongation, those Read the complete document